In addition to this dose-dependent effect, other studies have found that the dual effect of IFN-γ also varies according to the stage of disease progression, having a protective effect in the chronic stages of MS [47,48,49,50,51,52,53]. This evidence concerns the gene IFNG and myeloid sarcoma.